scispace - formally typeset
H

Henglei Lu

Researcher at Chinese Academy of Sciences

Publications -  22
Citations -  332

Henglei Lu is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 15 publications receiving 196 citations. Previous affiliations of Henglei Lu include Shanghai University.

Papers
More filters
Journal ArticleDOI

Hypoglycemic effect of the total flavonoid fraction from Folium Eriobotryae

TL;DR: The antidiabetic effect of the total flavonoids fraction from leaves of Eriobotrya japonica was evaluated through normal and streptozotocin-induced diabetic mice and suggested that EJF has hypoglycemic potential.
Journal ArticleDOI

Hypoglycemic and hypolipidemic effects of the total triterpene acid fraction from Folium Eriobotryae.

TL;DR: The evidences indicated that the total triperpene acid fraction from Folium Eriobotryae has a high anti-diabetic potential along with a good hypolipidemic profile.
Journal ArticleDOI

18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway.

TL;DR: 18b-GA confers hepatoprotection against ANIT-induced cholestasis by activating FXR through Sirt1, which promotes gene expression of the efflux transporter, and consequently attenuates dysregulation of bile acid homeostasis in hepatocyte compartments.
Journal ArticleDOI

Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy

TL;DR: In vitro and in vivo data indicate that miR-30b-5p may inhibit the TFEB-dependent transactivation by binding to the CLEAR elements in the nucleus to regulate the lysosomal biogenesis and autophagy.
Journal ArticleDOI

miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.

TL;DR: The mechanism of miR-552-3p modulating LXRα and FXR provided a new mode of miRNA-mediated gene regulation and suggested that it might be a potential therapeutic target for the treatment of glycolipid metabolic disease.